TRIB - Kewajiban jangka dawa marang modal trinitybiotech.com

Logo korporat perusahaan Trinity Biotech (TRIB)

Modern plants in the US and Ireland with strict purity controls ensure the profit stability of Trinity Biotech plc (TRIB). The trajectory of the long-term debt-to-equity ratio visualizes the financial leverage, while 0.00 expresses the latest level of the metric. Portable IT monitoring systems are driving sales growth, while leadership in diabetes diagnostics and the accuracy of rapid tests guarantee a steady cash flow from consumables.

Trinity Biotech Corp (TRIB): Utang jangka dawa marang modal saka 04.07.2022 nganti 27.10.2026
Barang utama Trinity Biotech PLC

To identify the sector's fundamental leaders, the analyst evaluates the stability of financial leverage. This ratio correlates liabilities with a maturity of over one year to equity, determining the business's degree of dependence on external financing. For Trinity Biotech plc (TRIB), packaging optimization and energy saving reduce costs, freeing up resources for debt service. Analyzing the long-term debt-to-equity structure allows for an assessment of asset freeze risks. A decrease in this metric confirms the protection of the company's value.

Karo sapa Trinity Biotech plc saingan

Rasio utang jangka dawa marang ekuitas Agilent Technologies, Inc.|Quest - Utang jangka dawa marang modal|Kewajiban jangka dawa marang modal Illumina Platform (ILMN)|EXAS - Utang jangka dawa marang modal|Rasio utang jangka dawa marang modal revvity.com RVTY|Bio-Rad - Utang jangka dawa marang modal|NNNN: Utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Sterigenics|QuidelOrtho Inc. (QDEL) - Rasio utang jangka dawa marang modal|OPK (OPKO Health, Inc.) - Utang jangka dawa marang modal|Utang jangka dawa marang modal CDNA|Utang jangka dawa marang ekuitas Maravai LifeSciences Holdings, Inc. (MRVI)|Utang jangka dawa marang ekuitas Fulgent Genetics Inc FLGT|LAB: Rasio utang jangka dawa marang ekuitas|Cytek Corp - Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas OSUR (OraSure Technologies)|XGN - Rasio tanggungan utang jangka dawa marang modal|MDxHealth - Utang jangka dawa marang modal|LUCD (Lucid Diagnostics, Inc.) - Rasio tanggungan utang jangka dawa marang modal|PRE: Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Insight Molecular (IMDX)|Rasio utang jangka dawa marang ekuitas ProPhase Labs, Inc.|Rasio silihan jangka dawa marang modal AIMD (ainos.com)|Utang jangka dawa marang ekuitas Co-Diagnostics|Koefisien utang jangka dawa marang modal Heart Test Laboratories, Inc. HSCS|Utang jangka dawa marang modal BMRA (Biomerica, Inc)|CDIO: Rasio tanggungan utang jangka dawa marang modal|Utang jangka dawa marang ekuitas Virax Biolabs Group|bluejaydx.com (BJDX) - Rasio utang jangka dawa marang modal|AWH: Utang jangka dawa marang modal|Rasio tanggungan utang jangka dawa marang modal Accelerate Diagnostics Inc. (AXDX)|Rasio utang jangka dawa marang ekuitas CENTOGENE, N.V.|Rasio silihan jangka dawa marang modal enzo.com ENZ|FRES: Rasio utang jangka dawa marang ekuitas|GENE - Kewajiban jangka dawa marang modal|Rasio utang jangka dawa marang ekuitas 23andMe (ME)|PMD - Koefisien utang jangka dawa marang modal